Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares gapped down before the market opened on Thursday . The stock had previously closed at $10.95, but opened at $10.68. Mesoblast shares last traded at $10.70, with a volume of 14,462 shares.
Analysts Set New Price Targets
A number of research firms have issued reports on MESO. Piper Sandler reaffirmed an "overweight" rating and issued a $24.00 price target (up previously from $15.00) on shares of Mesoblast in a research report on Friday, February 7th. Cantor Fitzgerald raised Mesoblast to a "strong-buy" rating in a report on Monday, March 31st. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $18.00.
Read Our Latest Analysis on Mesoblast
Mesoblast Stock Performance
The company has a debt-to-equity ratio of 0.21, a current ratio of 1.18 and a quick ratio of 1.18. The firm has a 50-day moving average of $11.26 and a 200 day moving average of $13.95.
Hedge Funds Weigh In On Mesoblast
Hedge funds have recently modified their holdings of the company. Strategic Financial Concepts LLC acquired a new position in shares of Mesoblast in the 4th quarter worth $2,744,000. Bank of America Corp DE boosted its position in Mesoblast by 1,503.3% during the fourth quarter. Bank of America Corp DE now owns 290,728 shares of the company's stock valued at $5,756,000 after purchasing an additional 272,595 shares during the last quarter. Quadrant Capital Group LLC boosted its position in Mesoblast by 41.1% during the fourth quarter. Quadrant Capital Group LLC now owns 6,496 shares of the company's stock valued at $129,000 after purchasing an additional 1,891 shares during the last quarter. LPL Financial LLC lifted its position in shares of Mesoblast by 7.7% in the fourth quarter. LPL Financial LLC now owns 38,882 shares of the company's stock worth $770,000 after buying an additional 2,795 shares during the last quarter. Finally, Barclays PLC acquired a new stake in shares of Mesoblast in the fourth quarter worth about $38,000. 1.43% of the stock is currently owned by institutional investors and hedge funds.
Mesoblast Company Profile
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
See Also
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
